Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Chris Anigeron Rallis sold 1,119 shares of the business's stock in a transaction on Monday, July 7th. The shares were sold at an average price of C$11.93, for a total transaction of C$13,352.69.
Chris Anigeron Rallis also recently made the following trade(s):
- On Monday, July 7th, Chris Anigeron Rallis sold 2,127 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$3.22, for a total transaction of C$6,847.88.
- On Friday, April 11th, Chris Anigeron Rallis sold 1,409 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$6.93, for a total transaction of C$9,764.37.
Fennec Pharmaceuticals Stock Down 4.4%
TSE:FRX traded down C$0.54 on Tuesday, hitting C$11.62. 1,243 shares of the company's stock were exchanged, compared to its average volume of 1,140. The firm has a 50-day moving average price of C$10.46 and a 200-day moving average price of C$9.36. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. Fennec Pharmaceuticals Inc. has a 52 week low of C$5.65 and a 52 week high of C$12.16. The company has a market cap of C$224.09 million, a P/E ratio of -196.84 and a beta of 0.25.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
